

MATERIALS LICENSE

DL-041895-01

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below, to use such material for the purpose(s) and at the place(s) designated below, to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

Licensee			
1.	Fairfax City Imaging Center	3. License Number	45-25326-01
2.	10721 Main Street Fairfax, Virginia 22030	4. Expiration Date	April 30, 2000
		5. Docket or Reference No.	030-33814

6. Byproduct, Source, and/or Special Nuclear Material	7. Chemical and/or Physical Form	8. Maximum Amount that Licensee May Possess at Any One Time Under This License
A. Any byproduct material identified in 10 CFR 35.100	A. Any unsealed byproduct material prepared for medical use that is identified in 10 CFR 35.100	A. As needed
B. Any byproduct material identified in 10 CFR 35.200	B. Any unsealed byproduct material prepared for medical use that is identified in 10 CFR 35.200 except radioactive gases	B. As needed
C. Iodine 131	C. Any capsule form prepared for medical use that is identified in 10 CFR 35.300	C. 55.5 gigabecquerels (1.5 curies)

9. Authorized Use:
- A. Medical use identified in 10 CFR 35.100.
 - B. Medical use identified in 10 CFR 35.200.
 - C. Any radiopharmaceutical therapy procedure approved in 10 CFR 35.300 for which the patient can be released under the provisions of 10 CFR 35.75.

CONDITIONS

10. Licensed material shall be used only at the licensee's facilities located at 10721 Main Street, Fairfax, Virginia.

9505110308 950418
PDR ADOCK 03033814
C PDR

11220

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number 45-25326-01

Docket or Reference Number 030-33814

Continued

CONDITIONS

11. The Radiation Safety Officer for this license is Robert S. Frankel, M.D.
12. Licensed material listed in Item 6 above is authorized for use by, or under the supervision of, the following individuals for the materials and uses indicated:
 - A. In accordance with 10 CFR 35.13(b)(1)(3) and (4), physicians, dentists, or podiatrists working as authorized users as defined in 10 CFR 35.2.
 - B. Licensed material listed in Item 6 above shall be used by, or under the supervision of, the following individuals for the materials and uses indicated:
 - (1) Robert S. Frankel, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (2) Jorge M. Garriala, M.D. Any medical use identified in CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (3) Philip S. Man, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (4) Verne F. Kemerer, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (5) Joseph Finizio, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (6) Rita Bass, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (7) Paul L. Weiner, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (8) Cecelia Holden, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (9) Elan C. Halperin, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.

MATERIALS LICENSE
SUPPLEMENTARY SHEET

License Number 45-25326-01

Docket or Reference Number 050-33814

CONDITIONS

12. (cont.)
- (10) Cheryl H. Troy, M.D. Any medical use identified in 10 CFR 35.100, 35.200 and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
 - (11) Ken Kin-Sing Au, M.D. Any medical use identified in 10 CFR 35.100, 35.200, and I-131 capsules for treatment of hyperthyroidism and/or cardiac dysfunction.
13. Sealed sources containing licensed material shall not be opened by the licensee.
14. In addition to the possession limits in item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35 for establishing decommissioning financial assurance.
15. The licensee shall maintain records of information important to safe and effective decommissioning, under 10 CFR 30.35(g), at the licensee's facilities listed in Condition 10. above, until this license is terminated by the Commission.
16. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below, except for minor changes in the medical use radiation safety procedures as provided in 10 CFR 35.31. The Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
- A. Application dated March 13, 1995 [new license]
 - B. Letter dated April 4, 1995 [Additional information about Radiation Safety Program]

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

EARL G. WRIGHT

Date APR 18 1995

By Earl G. Wright
 Region II, Nuclear Materials Licensing Section
 101 Marietta Street, Suite 2000
 Atlanta, GA 30323